Lonza Group AG
LZAGF
Other OTC727.70
USD
+20.19
- -
Lonza Group AG
LZAGF
(Other OTC)
Recent
price
727.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lonza Group AG is a Swiss multinational company engaged in supplying products and services to the pharmaceutical, biotechnology, and nutrition sectors. Founded in the late 19th century and headquartered in Basel, Switzerland, Lonza operates globally across Europe, North America, South America, Asia, and Oceania. The company's core offerings include contract development and manufacturing services (CDMO) for biologics, small molecules, and cell and gene therapy products; integrated biologics platforms; advanced chemical synthesis; specialized modalities; antimicrobials and preservatives for consumer health and nutrition; and drug delivery systems. Lonza divides its business into three strategic platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, having exited the Capsules and Health Ingredients segment, which historically accounted for approximately 17% of revenue. Recent major changes include the strategic decision announced in 2024 to exit the Capsules and Health Ingredients business to focus solely on CDMO services, aiming to simplify operations and enhance growth prospects. This shift includes a divestment process expected to complete by 2025, with prospective sales reflecting around CHF 6.6 billion annually. Lonza's 2024 financial performance demonstrated stable revenues with a CORE EBITDA margin of 29%, driven by strong growth and operational efficiency in its CDMO segment. Leadership transitions occurred with Jean-Marc Huët elected Chairman and Wolfgang Wienand beginning as CEO in 2024. The company also continues developing key capabilities in monoclonal antibodies and biologics manufacturing, positioning itself as a global leader in the pharmaceutical supply chain. Lonza’s geographic presence extends with major facilities across Europe, North America, and South Asia, supporting a broad customer base of pharmaceutical, biotech, and healthcare companies. The company maintains a commitment to innovation through acquisitions such as MODA Technology Partners, which enhances its informatics and rapid microbiology testing capabilities. Lonza’s strategic focus on becoming a pure-play CDMO emphasizes integrated drug development and manufacturing solutions, targeting complex therapies including biologics and specialized small molecules. This strategic evolution aligns with Lonza's positioning as a global partner delivering comprehensive pharmaceutical development and manufacturing services, custom biologics, chemical synthesis, cell and gene therapy manufacturing, antimicrobial products, and drug delivery technologies, with ongoing plans to refine its portfolio toward higher growth and operational efficiency sectors. Lonza Group AG remains publicly traded and continues to actively manage its portfolio with an emphasis on operational simplification, growth in integrated biologics, advanced synthesis platforms, and specialized modalities while divesting non-core segments to strengthen its market leadership and financial stability.
Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript